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Abstract
Background: Rotavirus was the leading cause of childhood diarrhoea-related hospitalisations and death before the
introduction of rotavirus vaccines.
Methods: We describe the effectiveness of rotavirus vaccines to prevent rotavirus infections and hospitalizations
and the main rotavirus strains circulating before and after vaccine introduction through a systematic review and
meta-analysis of studies published between 1990 and 2014. 203 studies were included to estimate the proportion
of infections due to rotavirus and 10 to assess the impact of the vaccines. 41 of 46 studies in the post-vaccination
period were used for meta-analysis of genotypes, 20 to calculate VE against infection, eight for VE against
hospitalisation and seven for VE against severe rotavirus-diarrhoea.
Results: 24.3 % (95 % CI 22.1–26.5) and 16.1 % (95 % CI 13.2–19.3) of cases of diarrhoea were due to rotavirus
before and after vaccine introduction, respectively. The most prevalent G types after vaccine introduction were G2
(51.6 %, 95 % CI 38–65), G9 (14.5 %, 95 % CI 7–23) and G1 (14.2 %, 95 % CI 7–23); while the most prevalent P types
were P[4] (54.1 %, 95 % CI 41–67) and P[8] (33 %, 95 % CI 22–46). G2P[4] was the most frequent genotype combination
after vaccine introduction. Effectiveness was 53 % (95 % CI 46–60) against infection, 73 % (95 % CI, 66–78) against
hospitalisation and 74 % (95 % CI, 68.0–78.0) against severe diarrhoea. Reductions in hospitalisations and mortality due
to diarrhoea were observed in countries that adopted universal rotavirus vaccination.
Conclusions: Rotavirus vaccines are effective in preventing rotavirus-diarrhoea in children in Latin America. The
vaccines were associated with changes in genotype distribution.
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Multilingual abstract
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Background
Diarrhoea is the second most important cause of child-
hood death worldwide and rotavirus is the pathogen
most frequently associated with severe diarrhoea [1].
More than 90 % of the deaths caused by rotavirus occur
in low and middle income countries [2] and in Latin
America (LA) alone, rotavirus diarrhoea caused >70 000
annual hospitalisations and 15 000 deaths between 1990
and 2009 [3].
In 2006, two live-attenuated rotavirus vaccines were
licensed [4, 5], which was followed in 2009 by the World
Health Organization (WHO) recommendation to in-
clude them in the national immunization programmes
of all countries with high diarrhoea-related child mortal-
ity [6]. The vaccines licensed were the pentavalent (G1,
G2, G3, G4, P[8]) human–bovine reassortant vaccine
(RotaTeq® (RV5); Merck, Whitehouse Station, NJ, USA)
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and the monovalent (G1P[8]) vaccine derived from an
attenuated human strain (Rotarix® (RV1); GlaxoSmithK-
line Biologicals, Rixensart, Belgium).
The LA region was among the early adopters of the vac-
cines with 16 countries and one territory introducing at
least one of these vaccines in their national immunization
programs. National programs have since reported signifi-
cant reductions in severe rotavirus-diarrhoea episodes, all-
cause diarrhoea-related hospitalisations and ambulatory
consultations [7–9].
Early reports also described that despite these reduc-
tions, a large proportion of rotavirus-diarrhoea episodes
were associated with the heterotypic G2P[4] genotype
[10, 11]. This is often attributed to a temporal coinci-
dence, as the genotype was circulating in countries with
and without rotavirus vaccinations [3]; and to immuno-
logical pressure, as the vaccines could have facilitated
the selection of genotypes for which they have lower effi-
cacy [12]. Although similar changes have been reported
from Belgium [13], Austria [14] and Australia [15]; a sys-
tematic review concluded that the genotype selection
was unlikely to be due to a selective pressure and that
further evidence is needed [16].
Rotavirus vaccines are being introduced in an increas-
ing number of countries and the oldest cohorts of vacci-
nated children are approaching 10 years. This large scale
regional experience has resulted in reports of vaccine
effectiveness (VE) to prevent severe diarrhoea and hospi-
talisations. Recently, a systematic review of reports pub-
lished between 2006 and 2013 estimated the VE against
hospitalisation to range from 63.5 to 72.2 % [17]. This
review however did not measure the impact of the vac-
cines on the burden of rotavirus infection or changes in
the frequency of rotavirus strains before and after vac-
cine introduction.
We conducted a systematic review and meta-analysis
to describe the effectiveness of the vaccines to prevent
rotavirus infection, hospitalisation and severe rotavirus-
diarrhoea in LA and the frequency of rotavirus geno-
types reported after vaccine introduction.
Methods
Search strategy and selection criteria
We conducted a systematic review using PubMed, the
Latin American and Caribbean Health Sciences Litera-
ture (LILACS) and SCOPUS databases to identify studies
published in Portuguese, Spanish and English between
January 1990 and September 2014. Publications were
identified using the search terms ≈rotavirus”, “rotavirus
infection”, “rotavirus vaccine” and related terms. The full
search strategy is described in the Additional file 2. Two
independent reviewers (VSS and DPM) screened the title
and abstract for relevance. Articles considered to have
original material were obtained and assessed in detail.
To assess the proportion of rotavirus in the pre- and
post-vaccination periods, we included all observational
studies (cohort, case-control, cross-sectional, case series
and surveillance) that included children under 5 years of
age with symptoms of acute gastroenteritis that had used
Enzyme Immune-Assay (EIA) or Enzyme Linked Immune-
Assays (ELISA) for the identification of rotavirus. There
were no clinical trials in the post-vaccination period. The
pre-vaccination period was considered the time prior to
the introduction of the vaccine in each country. For ex-
ample, Brazil introduced the vaccine in March 2006, con-
sequently all data reported from 1990 to before 2006 were
considered pre-vaccination.
All studies in the post-vaccination period were in-
cluded in the description of genotypes if they had used
reverse-transcription polymerase chain reaction (RT-
PCR). For the description of strain distribution, we in-
cluded studies reporting the number of samples tested
and the G and P combinations.
To evaluate VE against rotavirus infection, we used all
studies published in the post-vaccination period and to
assess VE against rotavirus-related hospitalizations and
severe diarrhoea, we included all case-control studies.
Studies reporting data before and after the introduc-
tion of the vaccine were used to assess the impact of the
vaccine on the burden of rotavirus disease.
We excluded clinical trials conducted before vaccine
licensure, articles without frequencies or percentages of
rotavirus-positive children, studies including children
with persistent diarrhoea (>2 weeks’ duration), those
reporting nosocomial infections, rotavirus B and C infec-
tions or limited to outbreaks. There were no clinical tri-
als conducted after the vaccines’ introduction and
therefore all studies included were observational.
Data extraction
Pre-defined tables for data extraction were developed
and piloted with 10 papers. The information extracted
included author, title, journal, publication year, country,
start and end dates, study design, sample size, number
of rotavirus-positive and negative samples (overall and
by vaccination status), age range, study setting (hospital,
hospital and community or community), vaccine type,
rotavirus vaccine coverage, proportion of cases due to
rotavirus, genotypes identified and frequency. Stool sam-
ples with rotavirus and co-infection with other patho-
gens were considered to be rotavirus-positive. Not all
studies reported all variables and percentages were cal-
culated using the number of studies reporting a given
variable as the denominator. Countries were classified
using the World Bank’s classification for economic de-
velopment [18] to describe the epidemiological context.
To assess VE against rotavirus infection, we extracted
the number of vaccinated and unvaccinated children
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who had rotavirus. To assess VE against rotavirus-
related hospitalisation and severe diarrhoea (defined as a
Vesikari score >11), we extracted the odds ratio and its
confidence interval from case-control studies. The stud-
ies’ quality was assessed by two independent reviewers
using the Newcastle-Ottawa Scale (NOS) [19].
Statistical analyses
Proportion of rotavirus diarrhoea and genotype distribution
The overall incidence of laboratory-confirmed rotavirus
diarrhoea and the proportion of P and G genotypes were
calculated using the variance-stabilizing Freeman-Tukey
double-arcsine transformation with an inverse-variance
random-effects model [20, 21]. We used a Bayesian esti-
mation for genotypes reported as 0 %. To make all pro-
portions different to zero we added 0.5 isolates to the
numerator and 1.0 isolates to the denominator. A Pareto
chart was prepared to display the strains and cumulative
genotype distribution.
The proportion of cases due to rotavirus diarrhoea by
country was calculated using the arcsine transformation in
a random-effects model. For countries with only one study,
the prevalence and 95 % confidence intervals (95 % CI)
were calculated according to Newcombe’s method [22].
Meta-analysis of single proportions was conducted in
RStudio (version 0.98.1083).
Vaccine effectiveness
We expressed the protective effect of the vaccines as the
relative odds reduction using the formula [100 % x (1-OR)].
The odds ratio (OR) was defined as the odds of
laboratory-confirmed rotavirus infection in vaccinated
patients divided by the odds of laboratory-confirmed
rotavirus infection in unvaccinated controls.
The overall protective effect of rotavirus vaccination
was estimated using the Mantel-Haenszel statistical
model. In addition, to assess the VE in preventing hospi-
talisations due to infectious diarrhoea (any severity) and
severe diarrhoea (Vesikari >11), the OR and CIs were en-
tered in the RevMan software (version 5.3; Cochrane
Collaboration) under the generic inverse variance out-
come. Forests plots were used to present the pooled OR
and 95 % CI. Two-sided P-values <0.05 were considered
statistically significant.
Heterogeneity was investigated by the chi-squared test
for heterogeneity and quantified using the I2 index
[100 % x (Q-df )/Q] [23]. The I2 value ranged from 0 to
100 %, with 25, 50 and 75 % expressing low, moderate
and high heterogeneity, respectively. When I2 > 25 %, a
random-effects model was applied to estimate the
pooled results. Otherwise, the fixed-effects model was
used.
Potential sources of heterogeneity were explored by
comparing results grouped according to study-level
characteristics and by using meta-regression to assess
the significance of the differences. The characteristics
explored were the vaccine type (RV1 vs. RV5), income
(lower middle income vs. upper middle income coun-
tries), setting (hospital vs. hospital and community vs.
community), latitude, and vaccination coverage. R2 index
was used to quantify the proportion of variance ex-
plained by the covariates [23]. The assumptions of nor-
mality, independence, and homogeneity of residuals
were verified using diagnostic plots.
Publication bias was assessed using funnel plots of the
individual estimates in log units against the standard
error and regression tests were performed to analyse the
plot asymmetry.
Results
The search strategy identified 7 151 records. After screen-
ing titles and abstracts, 392 full-text articles were assessed
for eligibility and 215 were included. Of these, 203 were
used to estimate the proportion of rotavirus, 157 in the
pre-vaccine and 46 in the post-vaccine periods. Forty-one
of the latter studies were used for genotype meta-analysis.
VE was estimated based on 20 studies that reported the
number of vaccinated and unvaccinated children. Of
these, nine reported data on VE against hospitalisation
and/or severe rotavirus-diarrhoea (Fig. 1).
One hundred and thirty-nine (64.6 %) of the 215 studies
selected were cross-sectional, 29 (13.4 %) cohorts, 21
(9.7 %) case-control, 14 (6.5 %) surveillance and nine
(4.2 %) case series. Two hundred five (95.3 %) studies were
hospital-based, eight (3.7 %) hospital and community-
based and 15 (6.9 %) community-based (Additional file 2).
Proportion of rotavirus diarrhoea and genotype
distribution
Data extracted from 157 studies in the pre-vaccination
period estimated that 24.3 % (95 % CI 22.1–26.5) were
due to rotavirus. In the post-vaccination period, 46
studies provided data on the proportion of rotavirus
cases (Additional file 2: Table S1). Overall, 9 948
(16.1 %, 95 % CI 13.2–19.3) of 67,048 children tested for
rotavirus infection were rotavirus-positive with the low-
est and highest proportion of rotavirus-positive cases be-
ing reported from Nicaragua (10.5 %, 95 % CI 6.3–15.6)
and Mexico (26.7 %, 95 % CI 17.1–39.0), respectively.
There was high-level heterogeneity across the studies
(I2 = 99.1 %, P < 0.001). Table 1 describes the proportion
of children with rotavirus-positive diarrhoea by country in
the pre- and post-vaccination periods.
G and P type information was available for 5 920 and
5 845 isolates from 41 studies (Table 2). Most isolates were
reported from Brazil, Nicaragua, and Colombia. G2 was
the most prevalent G type (51.6 %, 95 % CI 37.8–65.3),
followed by G9 (14.5 %, 95 % CI 7.4–23.0) and G1
Santos et al. Infectious Diseases of Poverty  (2016) 5:83 Page 3 of 12
(14.2 %, 95 % CI 6.9–23.3). The most common P
types were P[4] (54.1 %, 95 % CI 41.3–66.5), P[8]
(33.2 %, 95 % CI 21.9–45.5), and P[6] (3.9 %, 95 % CI
1.7–6.7).
G2P[4] was the most prevalent G/P combination in
Brazil (54.2 %, 95 % CI 32.8–74.9), Argentina (46.6 %,
95 % CI 38.9–54.4), Ecuador (50.0 %, 95 % CI 33.6–66.4)
and Colombia (57.3 %, 95 % CI 27.1–84.8) and the second
most common combination in Nicaragua (20.3 %, 95 % CI
0.2–54.6), Chile (6.8 %, 95 % CI 4.0–11.3) and Bolivia
(28.9 %, 95 % CI 23.7–34.7). The G9P [8] combination
was most frequent in Chile (81.7 %, 95 % CI 75.6–86.5)
and Bolivia (41.8 %, 95 % CI 35.9–47.9); and the second
most frequent in Argentina (16.4 %, 95 % CI 1.3–41.8 %),
Ecuador (37.5 %, 95 % CI 22.9–54.8), and Colombia
(7.8 %, 95 % CI 3.0–14.4). G1P[8] (32.9 %, 95 % CI
6.2–66.7), G9P[4] (100 %, 95 % CI 80.6–100), and
G12P[6] (33.3 %, 95 % CI 19.2–51.2) combinations
were the main genotypes in Nicaragua, Mexico and
Peru, respectively (Fig. 2).
Vaccine effectiveness
Twelve studies from upper-middle income countries
(Argentina [24], Brazil [8, 10, 25–31], Mexico [32], and
Venezuela [33]) and lower-middle income countries
(Bolivia [34], El Salvador [35], and Nicaragua [36–41]),
involving 15 750 children were included for the overall
analysis of VE. These included 2 102 (17.4 %) rotavirus-
positive cases among 12 079 vaccinated and 996 (27.1 %)
rotavirus-positive cases among 3 671 unvaccinated
Fig. 1 Flow diagram of study selection
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children. The overall OR was 0.47 (95 % CI 0.40–0.54),
resulting in an overall VE against diarrhoea infection of
53 % (95 % CI 46.0–60.0). VE was similar for RV1 (54 %,
95 % CI 45.0–62.0) and RV5 (52 %, 95 % CI 36.0–64.0)
(P = 0.79) (Fig. 3). There was moderate between-study
heterogeneity (P = 0.08; I2 = 33 %).
VE to prevent diarrhoea-related hospitalisations (of
any severity) and severe rotavirus-diarrhoea was based
on eight [26, 34, 35, 40–44] and seven [26, 29, 33, 34,
37, 39, 44] case-control studies, respectively. VE against
rotavirus-related hospitalisations was 73 % (95 % CI,
66.0-78.0), with moderate heterogeneity among studies
(I2 = 29 %, P = 0.20). VE against severe rotavirus diar-
rhoea was 74 % (95 % CI, 69.0–78.0) with no evidence
of heterogeneity (I2 = 0 %, P = 0.55). The level of protec-
tion was similar for the two vaccines, as shown in
Fig. 4.
To investigate the potential sources of heterogeneity
among studies, a meta-regression analysis was per-
formed by using variables as type of vaccine, setting,
country income, latitude, and vaccination coverage.
Although the difference in protection by latitude was
not significant in meta-regression (P = 0.258), it was the
only factor that partly explained the heterogeneity (ad-
justed R2 = 22.3 %) (Additional file 2: Table S2).
The omission of any of the studies did not modify vac-
cine effectiveness, suggesting a high stability of the
meta-analysis. There was no evidence of publication bias
(Additional file 2: Figure S1).
Twelve studies assessed the impact of rotavirus vaccin-
ation in countries adopting universal rotavirus vaccin-
ation. Of these, five were conducted in Brazil [7, 44–48],
four in Mexico [49–52], two in Panama [53, 54] and one
in El Salvador [55]. In Brazil, vaccine coverage ranged
from 80 % in 2007 to 86 % in 2009. A substantial reduc-
tion in deaths (22.0 % to 54.5 % reduction) and hospitali-
zations (25.0 % to 50.0 % reduction) in children <1 year
old was observed, compared to the pre-vaccination
period. In Mexico, vaccination coverage remained above
90 % from 2006 to 2011 with significant reductions in
deaths and hospitalisations due to gastroenteritis. In
Panama, national hospital database studies comparing
Table 1 Proportion of children with rotavirus diarrhoea pre- and post-vaccination in Latin America
Country Year of introduction
rotavirus vaccine
Vaccine Pre vaccine Post vaccine Difference (%)
Proportion CI 95 % Proportion CI 95 %
Brazil 2006 RV1 21.1 17.7–24.7 15.8 11.4–20.8 −25.1
El Salvador 2006 RV1 32.9 25.7–40.7 19.7 18.9–20.6 −40.1
Panama 2006 RV1 24.8 3.8–56.4 - - -
Venezuela 2006 RV1 21.7 16.9–26.9 - - -
Nicaragua 2007 RV5 18.9 14.8–23.6 10.5 6.3–15.6 −44.4
Bolivia 2008 RV1 28.9 16.4–43.3 17.3 15.8–18.9 −40.1
Ecuador 2008 RV1 30.0 20.8–40.1 18.8 15.3–22.9 −37.3
Peru 2008 RV1 24.9 16.7–34.1 - - -
Colombia 2009 RV1 29.8 19.1–41.8 18.4 16.1–20.8 −38.3
Honduras 2009 RV1 27.5 14.9–42.3 - - -
Mexico 2009 RV1 19.8 12.3–28.5 26.7a 17.1–39.0 +34.8
Guatemala 2010 RV1 30.4 13.2–50.9 - - -
Guyana 2010 RV1 8.1 5.5–10.1 - - -
Paraguay 2010 RV1 25.3 19.4–31.7 - - -
Dominican Republic 2012 RV1 61.9 57.1–66.6 - - -
Argentina - - 26.4 19.9–34.2 - - -
Chile - - 26.4 19.5–33.9 - - -
Costa Rica - - 44.7 32.6–57.1 - - -
Cuba - - 16.6 5.2–32.7 - - -
Puerto Rico - - 15.6 14.8–16.4 - - -
St. Vincent - - 25.2 18.1–33.0 - - -
Surinam - - 33.9 28.3–39.9 - - -
Uruguay - - 37.2 26.5–48.4 - - -
aBased on only one study
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diarrhoea-related hospitalisations and deaths prior
(2000–2005) and after (2008) vaccination reported a
45 % reduction in hospitalisations and 50 % of deaths
among infants aged <1 year old. Rotavirus vaccine cover-
age at that time was above 80 %. El Salvador reported a
reduction in hospitalisation rates. Rotavirus vaccine
coverage in 2008 and 2009 was 74 and 89 %, respectively
(Table 3).
Discussion
Rotavirus-related diarrhoea is still an important public
health problem in low- and middle-income countries
and the early and widespread use of the vaccines in LA
has resulted in a large number of studies and samples
analysed, providing an excellent opportunity for their
post-licensure evaluation. This meta-analysis estimated
that rotavirus VE was 53 % against rotavirus infec-
tions, 73 % against rotavirus-related hospitalisations
and 74 % against severe diarrhoea episodes. The vac-
cines (RV1 and RV5) had similar effectiveness. These
findings highlight the occurrence of significant reduc-
tions of hospitalisations and deaths, as well as de-
creases in the proportion of diarrhoea episodes due
to rotavirus among the countries that adopted univer-
sal rotavirus vaccination.
The trials conducted for the registration of the vac-
cines included a large number of children from middle-
and high-income countries from Europe, North America
and LA and their main end-points focused on severe
diarrhoea episodes and hospitalisation. Their efficacy
against severe rotavirus-diarrhoea ranged from 85 to
98 % and rotavirus-associated hospitalisation ranged
from 85 to 94 % [4, 5]. In these trials however, vaccine
efficacy for all-cause diarrhoea hospitalisation was only
39 % and data on the efficacy of the vaccines to reduce
infections was not reported [56]. Our findings reflect
real-world outcomes, that are different from those re-
ported under clinical trial conditions and seem to be
lower than in Europe, where VE against hospitalisations
ranges from 80 to 98 % [57]. There seems to be a vari-
ation of the protective effect of the vaccine according to
the setting, and trials in low/middle-income African
Table 2 Rotavirus G and P genotype distribution in Latin
America, 2006–2014
Genotype Isolates (n) Proportion (%) 95 % CI
G1 1 501 14.2 6.9–23.3
G2 3 170 51.6 37.8–65.3
G3 335 3.6 1.7–6.0
G4 97 0.3 0.0–0.8
G5 33 0.0 0.0–0.2
G8 29 0.0 0.0–0.04
G9 703 14.5 7.4–23.0
G10 1 0.0 0.0–0.2
G12 50 0.8 0.1–1.9
G un-typeable 90 1.2 0.2–2.6
P[4] 3 208 54.1 41.3–66.5
P[6] 327 3.9 1.7–6.7
P[8] 2 265 33.2 21.9–45.5
P[9] 1 0.0 0.0–0.1
P[10] 5 0.0 0.0–0.2
P un-typeable 111 2.2 0.8–4.2
The proportions of genotypes were calculated by using random-effects model
Fig. 2 Geographical areas in which rotavirus genotypes are prevalent
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countries have reported a lower efficacy of the RV1 vac-
cine [58, 59], which could be due to the higher burden
of disease in these settings.
This meta-analysis reinforces that the introduction of
the vaccines reduces hospitalisations, and reduces the
frequency of severe rotavirus episodes and deaths in
children <5 years old. The studies summarised provide
significant evidence of reductions in hospitalisations and
deaths not only in children that received the vaccines,
but also in older children. Similar data have been re-
ported from Europe [57] and the United States [9],
which may be due to a herd effect of the vaccine enhan-
cing its impact when implemented at large scale under
routine conditions. The reduction in hospitalisations and
deaths would result in large cost savings [60]. It is esti-
mated that from 2007 to 2025, universal vaccination
could avert 141 medical visits for every 1000 children
vaccinated in Latin America and save >16 000 lives [61].
Overall, our findings show a decrease in the propor-
tion of diarrhoea infections by rotavirus in the post-
vaccine era and provide further evidence that rota-
virus vaccinations are associated with a reduction in
rotavirus-diarrhoea morbidity. The 16 % proportion of
children with rotavirus infection is much lower than
the proportion reported before vaccination introduc-
tion (range 24–47 %) [3, 62, 63], but varied consider-
ably among countries. This variability may be explained
by differences in the burden of disease across study set-
tings, the case definitions used; that some countries were
represented by only one study and that some studies were
conducted soon after vaccine introduction, which compli-
cates the interpretation of data.
Historically, rotavirus genotypes before vaccines intro-
duction varied over time and the peak frequency of one
strain was often followed by a trough and replacement
by a different genotype [64]. The strains found most
commonly in LA before vaccines introduction were
G1P[8], G9P[8] and in a lower proportion G2P[4] and
these strains were similar to the most frequent geno-
types reported worldwide [3, 64, 65]. After the introduc-
tion of the vaccines, a high proportion of studies
reported that the highest number of cases were due to
the G2P[4], especially in countries that adopted the RV1
vaccine. Similar changes were observed in Oceania
[15] and Europe [13, 14, 66]. Latin American coun-
tries that did not adopt the vaccines up to 2012 (e.g.
Cuba, Costa Rica and Dominican Republic) reported
that a different strain (G9P[8]) was the most frequent
circulating genotype (>75 %) among their children
with diarrhoea [67, 68].
A recent meta-analysis reported that vaccine protec-
tion against the G2P[4] strain is lower (39 % in Latin
America and 58 % in Europe) than for homotypic and
partly-heterotypic strains (>80 % protection) [16], sug-
gesting that the RV1 vaccine may have favoured the
selection of this strain in a highly vaccinated popula-
tion [69]. However, a recent study in Brazil also re-
ported a decrease of G2P[4] incidence from 2011
Fig. 3 Forest plot of rotavirus vaccine effectiveness against rotavirus infection
Santos et al. Infectious Diseases of Poverty  (2016) 5:83 Page 7 of 12
onwards and that other genotypes, such as G8P[4],
G8P[6] and G3P[8] had become more frequent, sug-
gesting that whatever the mechanism underlying these
changes, genotype variation is likely to continue after
vaccine introduction [70]. Further studies are needed
to ascertain if the genotypes in the future represent al
strains, of if genotypes for which the vaccines have
lower efficacy are over-represented.
Our results should be treated with caution as the re-
ports included have study design limitations as they used
descriptive and/or ecological designs, which are not suit-
able to demonstrate causality. The proportion of cases
due to rotavirus and genotype distributions were based
on studies with different designs and laboratory methods
to identify and characterise rotavirus strains. There was
a high heterogeneity among the studies used to calculate
the meta-proportion of rotavirus incidence. To counter
this heterogeneity, we used the random effects model to
minimise its impact on summary estimations. In some
locations, the rotavirus proportion and genotype
distribution was based on a single study reporting six
countries. Countries which have not adopted the vaccine
on a large scale, such as Chile and Argentine, allow pri-
vate practitioners to provide rotavirus vaccinations,
which provides services for a selected population of high
and middle-income children. Finally, some studies re-
ported data for one year, restricting our ability to de-
scribe strain changes over time.
Conclusions
Post-licensure studies have reported that rotavirus vac-
cines are effective in preventing rotavirus infection in sub-
stantial numbers of children in LA. This evidence
strengthens the importance of the vaccines as an effective
intervention for reducing the burden of diarrhoea and on
rotavirus-specific diarrhoea. Continued surveillance after
vaccine introduction is needed to monitor the long-term
changes in rotavirus incidence and the potential emer-
gence of heterotypic strains.
Fig. 4 Effectiveness of rotavirus vaccines against rotavirus hospitalisation (a) and severe rotavirus-diarrhoea (b)
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Table 3 Impact of rotavirus vaccination on hospitalisation and mortality due to diarrhoea in Latin America
Study Country Vaccine Outcome Pre-vaccination Post-vaccination Difference (%)
Diarrhoea mortality Year Results Year Results
do Carmo 2011 [7] Brazil RV1 Annual death rates/100 000 children 2002–2005 <1 yr: 48 2007–2009 <1 yr: 35 −22
1 yr: 11 1 yr: 7 −28
2–4 yr: 1 2–4 yr: 1 −4
All: 12 All: 9 −22
Gurgel 2011 [45] Brazil RV1 Number of hospitalisation 2002–2005 <1 yr: 986 2006–2009 <1 yr: 449 −54.5
1–4 yr: 237 1–4 yr: 159 −32.9
All: 1 223 All: 608 −50.3
Lanzieri 2011 [46] Brazil RV1 Annual death rates/100 000 children 2004–2005 <1 yr: 56.9 2008 <1 yr: 34.9 −39
1–4 yr: 4.5 1–4 yr: 3.0 −33
Richardson 2010 [49] Mexico RV1 Annual death rates/100 000 children 2003–2006 <1 yr: 61.5 2008 <1 yr: 25.5 −41
1–2 yr: 21.1 1–2 yr: 6.1 −29
2–5 yr: 2.9 2–5 yr: 0.2 −7
All: 18.1 All: 6.3 −35
Gastañaduy 2013 [50] Mexico RV1 Annual death rates/100 000 children 2003–2006 <1 yr: 59.1 2009–2011 <1 yr: 28.4 −52
1–2 yr: 19.6 1–2 yr: 7.9 −60
2–5 yr: 2.8 2–5 yr: 2 −26
All: 17 All: 8.5 −50
Bayard 2012 [53] Panama RV1 Annual death rates/100 000 children 2000–2005 <1 yr: 73 2008 <1 yr: 40 −45
1–4 yr: 20.3 1–4 yr: 9 −54
All: 31.1 All: 15.5 −50
Diarrhoea hospitalisation
do Carmo 2011 [7] Brazil RV1 Hospitalisation rates/100 000 children 2002–2005 <1 yr: 2 477 2007–2009 <1 yr: 1 840 −25
1 yr: 2 487 1 yr: 1 886 −21
2–4 yr: 774 2–4 yr: 722 −7
All: 1 429 All: 1 165 −17
Gurgel 2011 [45] Brazil RV1 Number of hospitalisation 2002–2005 <1 yr: 194 348 2006–2009 <1 yr: 125 151 −35.6
1–4 yr: 301 479 1–4 yr: 264 376 −12.3
All: 495 827 All: 389 527 −21.4
Masukawa 2014 [47] Brazil RV1 Hospitalisation rates/100 000 children 2000–2005 <1 yr: 255.8 2007–2011 <1 yr: 163.9 −35.9
1 yr: 241.5 1 yr: 181.3 −24.9
2 yr: 133.2 2 yr: 118.3 −11.2
3 yr: 83.4 3 yr: 76.5 −8.3
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Table 3 Impact of rotavirus vaccination on hospitalisation and mortality due to diarrhoea in Latin America (Continued)
Fernandes 2014 [48] Brazil, São Paulo State RV1 Hospitalisation rates/100 000 children 2000–2005 <1 yr: 1 009.3 2008–2011 <1 yr: 504.5 −50
1 yr: 743.1 1 yr: 442.5 −40
2–4 yr: 385.4 2–4 yr: 279.7 −27
All: 630.8 All: 376.6 −40
Yen 2011 [55] El Salvador RV1 Hospitalisation rates/100 000 children 2005–2006 <1 yr: 499 2008 <1 yr: 79 −84
1–2 yr: 447 1–2 yr: 63 −86
2–3 yr: 123 2–3 yr: 43 −65
3–4 yr: 30 3–4 yr: 18 −41
4–5 yr: 26 4–5 yr: 8 −68
All: 225 All: 42 −81
Yen 2011 [55] El Salvador RV1 Hospitalisation rates/100 000 children 2005–2006 <1 yr: 499 2009 <1 yr: 106 −79
1–2 yr: 447 1–2 yr: 96 −79
2–3 yr: 123 2–3 yr: 67 −46
4–5 yr: 26 4–5 yr: 23 −11
All: 225 All: 70 −69
Quintanar-Solares 2011 [52] Mexico RV1 Number of hospitalisation 2003–2006 <1 yr: 5 133 2009 <1 yr: 6 597 −40
1–2 yr: 3 944 1–2 yr: 2 441 −52
2–5 yr: 1 853 2–5 yr: 2 265 −43
Esparza-Aguilar 2014 [51] Mexico RV1 Hospitalisation rates/10 000 children 2003–2006 <1 yr: 684 2008–2011 <1 yr: 358 −48
1–2 yr: 2 301 1–2 yr: 1 195 −48
2–5 yr: 888 2–5 yr: 733 −18
All: 945 All: 590 −38
Molto 2011 [54] Panama RV1 Number of hospitalisation 2000–2005 <1 yr: 1 359 2008 <1 yr: 941 −31
1–4 yr: 2 698 1–4 yr: 1 614 −40
All: 4 057 All: 2 555 −37
Bayard 2012 [53] Panama RV1 Number of hospitalisation 2000–2005 <1 yr: 1 062 2008 <1 yr: 762 −28
1–4 yr: 1 942 1–4 yr: 1 347 −31
All: 3 004 All: 2 109 −30
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